Ra Pharmaceuticals Initiated with a Buy at BMO Capital


BMO Capital analyst Ian Somaiya initiated coverage with a Buy rating on Ra Pharmaceuticals (NASDAQ: RARX) today and set a price target of $20. The company’s shares closed yesterday at $10.94.

According to TipRanks.com, Somaiya is ranked #433 out of 4840 analysts.

Currently, the analyst consensus on Ra Pharmaceuticals is a Moderate Buy with an average price target of $18.

See today’s analyst top recommended stocks >>

Based on Ra Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $16.5 million. In comparison, last year the company had a GAAP net loss of $12.66 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of peptide-based drugs for a variety of therapeutic uses. The firm’s lead product, RA101495 SC, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts